| Literature DB >> 24314589 |
Francesca R Mauro1, Stefano Molica2, Luca Laurenti3, Agostino Cortelezzi4, Angelo M Carella5, Francesco Zaja6, Annalisa Chiarenza7, Francesco Angrilli8, Francesco Nobile9, Roberto Marasca10, Caterina Musolino11, Maura Brugiatelli12, Alfonso Piciocchi13, Marco Vignetti13, Paola Fazi13, Giuseppe Gentile14, Maria S De Propris14, Irene Della Starza14, Marilisa Marinelli14, Sabina Chiaretti14, Ilaria Del Giudice14, Mauro Nanni14, Francesco Albano15, Antonio Cuneo16, Anna Guarini14, Robin Foà14.
Abstract
In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.Entities:
Keywords: Alemtuzumab; Biology; CLL; Chronic lymphocytic leukemia; Fludarabine; Young
Mesh：
Substances：
Year: 2013 PMID： 24314589 DOI： 10.1016/j.leukres.2013.11.009
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156